NextCure NXTC
NASDAQ NXTC
$6.40 +0.17 (+2.73%)
At close: Nov 13, 2026 · 4:00 PM EST

NextCure (NXTC) Non-Current Deferred Revenue (2018 - 2019)

Updated

NextCure (NXTC) reported Non-Current Deferred Revenue of $15.95 million for Q4 2019, down 26.6% from $21.74 million a year earlier and down 9.8% from the prior quarter.

Analysis

NextCure (NXTC) Non-Current Deferred Revenue (2018 - 2019) Analysis & Trends

Dating back to Q4 2018, NextCure's Non-Current Deferred Revenue record includes 4 quarters.

  • By year, Non-Current Deferred Revenue came in at $21.74 million in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 NextCure 29.30 Mn -71.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 15.95 Mn
Sep 30, 2019 17.68 Mn
Jun 30, 2019 18.44 Mn
Dec 31, 2018 21.74 Mn
API Access

NextCure Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=NXTC&period=max&api_key=YOUR_API_KEY